Overview

Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder

Status:
Not yet recruiting

Trial end date:
2023-11-01

Target enrollment:

Participant gender:

Summary

The primary objective of this trial is to determine whether tAN can improve relapse prevention beyond that seen with depot naltrexone during Phase II.

Phase:

N/A

Details

Lead Sponsor:

Spark Biomedical, Inc.

Treatments:

Lofexidine
Naltrexone